STOCK TITAN

Organigram to Report Fourth Quarter and Full Year Fiscal 2020 Results on November 30, 2020

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Organigram Holdings Inc. (NASDAQ: OGI) announced it will report earnings results for the fourth quarter and full year Fiscal 2020, ending August 31, 2020, on November 30, 2020, before the market opens. A conference call will follow at 8:00 AM Eastern Time on the same day to discuss these results. Investors can register for the call and access a webcast through provided links. Organigram focuses on producing high-quality cannabis products in Canada and expanding internationally, operating under regulations outlined by the Cannabis Act.

Positive
  • Scheduled report of earnings results for Q4 and full year FY2020 could provide valuable financial insights.
  • Focus on high-quality, indoor-grown cannabis aligns with consumer demand and market trends.
Negative
  • None.

MONCTON, New Brunswick--()--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and full year Fiscal 2020 ended August 31, 2020 on Monday November 30th, 2020 before market open.

The Company will host a conference call to discuss the results:

Date:

November 30, 2020

Time:

8:00am Eastern Time

To register for the conference call, please use this link: http://www.directeventreg.com/registration/event/4687978

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast: https://event.on24.com/wcc/r/2625442/2C164D33CA068A822C82053411FBA767

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada. 

Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics, SHRED and Trailblazer. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contacts

For Investor Relations enquiries, please contact:
Amy Schwalm
Vice President, Investor Relations
amy.schwalm@organigram.ca
(416) 704-9057

For Media enquiries, please contact:
Marlo Taylor
mtaylor@gagecommunications.ca

FAQ

When will Organigram report its earnings results for Q4 FY2020?

Organigram will report its earnings results for the fourth quarter and full year FY2020 on November 30, 2020, before market open.

What time is the Organigram earnings conference call scheduled?

The earnings conference call is scheduled for 8:00 AM Eastern Time on November 30, 2020.

How can investors access the webcast for Organigram's earnings call?

Investors can access the webcast for Organigram's earnings call through the provided link in the press release.

What is Organigram Holdings Inc.'s focus in the cannabis market?

Organigram is focused on producing high-quality, indoor-grown cannabis for both medical and adult recreational consumers in Canada, while also pursuing international business partnerships.

Organigram Holdings Inc. Common Shares

NASDAQ:OGI

OGI Rankings

OGI Latest News

OGI Stock Data

166.12M
75.87M
31.32%
9.73%
2.11%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Toronto